<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on February 03, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00002482</url>
  </required_header>
  <id_info>
    <org_study_id>CDR0000077247</org_study_id>
    <secondary_id>SVMC-ONC-121</secondary_id>
    <secondary_id>NCI-V90-0206</secondary_id>
    <nct_id>NCT00002482</nct_id>
  </id_info>
  <brief_title>Monoclonal Antibody Plus Cyclophosphamide in Treating Patients With Metastatic Cancer</brief_title>
  <official_title>A PHASE I-II TRIAL OF MUROMONAB (OKT-3) WITH LOW-DOSE CYCLOPHOSPHAMIDE</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>St. Vincent Medical Center - Los Angeles</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Cancer Institute (NCI)</source>
  <brief_summary>
    <textblock>
      RATIONALE: Monoclonal antibodies can locate tumor cells and either kill them or deliver&#xD;
      tumor-killing substances to them without harming normal cells.&#xD;
&#xD;
      PURPOSE: Phase I/II trial to study the effectiveness of monoclonal antibody and&#xD;
      cyclophosphamide in treating patients with metastatic cancer.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES: I. Evaluate the clinical feasibility and toxicity of monoclonal antibody OKT3&#xD;
      given with low-dose cyclophosphamide in patients with advanced malignancies. II. Perform&#xD;
      serial immune monitoring on patients treated with this regimen. III. Identify any clinical&#xD;
      responses produced by this regimen.&#xD;
&#xD;
      OUTLINE: Biological Response Modifier Therapy with Suppressor Cell Inhibition. Anti-CD3&#xD;
      Murine Monoclonal Antibody OKT3, MOAB OKT3; with Cyclophosphamide, CTX, NSC-26271.&#xD;
&#xD;
      PROJECTED ACCRUAL: At least 9 evaluable patients per diagnostic category will be required&#xD;
      initially; if any response is seen during the dose-finding portion of the study, a total of&#xD;
      24 patients with that diagnosis will be entered.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Active, not recruiting</last_known_status>
  <start_date>June 1991</start_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <primary_purpose>Treatment</primary_purpose>
  </study_design_info>
  <condition>Unspecified Adult Solid Tumor, Protocol Specific</condition>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>antibody therapy</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>biological therapy</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>muromonab-CD3</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>cyclophosphamide</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS: Metastatic cancer considered incurable by standard therapy and for&#xD;
        which no higher priority protocol is available Locally progressive primary brain tumors&#xD;
        (e.g., astrocytoma, glioma) are also eligible Brain metastases allowed&#xD;
&#xD;
        PATIENT CHARACTERISTICS: Age: 18 and over Performance status: ECOG 0-4 (poor performance&#xD;
        status brain tumor patients specifically eligible) Life expectancy: At least 2 months&#xD;
        Hematopoietic: Not specified Hepatic: Not specified Renal: Not specified Pulmonary: No&#xD;
        history of adult asthma No emphysema No pulmonary insufficiency No pulmonary edema Other:&#xD;
        No AIDS or positive HIV serology No pregnant women&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY: Biologic therapy: Not specified Chemotherapy: Not specified&#xD;
        Endocrine therapy: Not specified Radiotherapy: Not specified Surgery: Not specified&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Charles L. Wiseman, MD, FACP</last_name>
    <role>Study Chair</role>
  </overall_official>
  <location>
    <facility>
      <name>St. Vincent Medical Center - Los Angeles</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90057</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2007</verification_date>
  <study_first_submitted>November 1, 1999</study_first_submitted>
  <study_first_submitted_qc>June 25, 2004</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 28, 2004</study_first_posted>
  <last_update_submitted>November 5, 2013</last_update_submitted>
  <last_update_submitted_qc>November 5, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 6, 2013</last_update_posted>
  <keyword>unspecified adult solid tumor, protocol specific</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cyclophosphamide</mesh_term>
    <mesh_term>Muromonab-CD3</mesh_term>
    <mesh_term>Antibodies</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

